Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. (Q37959271)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105373%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105373%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105373%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

P Zarogoulidis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105373%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

N Papanas

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105373%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

I Kioumis

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105373%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

E Chatzaki

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105373%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

K Zarogoulidis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105373%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

22 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105373%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Clinical Pharmacology

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105373%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

68

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105373%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105373%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

479-503

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105373%20AND%20SRC:MED&resulttype=core&format=json

Evolution of Mycobacterium ulcerans and other mycolactone-producing mycobacteria from a common Mycobacterium marinum progenitor

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Large sequence polymorphisms unveil the phylogenetic relationship of environmental and pathogenic mycobacteria related to Mycobacterium ulcerans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Immunomodulatory activity and effectiveness of macrolides in chronic airway disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Clarithromycin has an immunomodulatory effect on ERK-mediated inflammation induced by Pseudomonas aeruginosa flagellin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Antimicrobial and immunomodulatory effect of clarithromycin on macrolide-resistant Mycoplasma pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Effects of immunomodulatory drugs on plasma inflammatory markers in a rabbit model of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Mechanisms of action and clinical application of macrolides as immunomodulatory medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Telithromycin inhibits the production of proinflammatory mediators and the activation of NF-kappaB in in vitro-stimulated murine cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Immunomodulatory effect of three-day continuous administration of clarithromycin for experimental sepsis due to multidrug-resistant Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Immunomodulatory effects of erythromycin and its derivatives on human T-lymphocyte in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Telithromycin in lower respiratory tract infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

The anti-inflammatory effects of macrolides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Effects of telithromycin in in vitro and in vivo models of lipopolysaccharide-induced airway inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Immunomodulatory effects of macrolide antibiotics - part 1: biological mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Effect of clarithromycin on lung inflammation and alveolar macrophage function in Klebsiella penumoniae B5055-induced acute lung infection in BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Pharmacogenomics and adverse drug reactions: the case of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Macrolide antibiotics improve chemotactic and phagocytic capacity as well as reduce inflammation in sulfur mustard-exposed monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Clarithromycin suppresses airway hyperresponsiveness and inflammation in mouse models of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Azithromycin attenuates airway inflammation in a noninfectious mouse model of allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Effect of clarithromycin on the cell profile of bronchoalveolar lavage fluid in mice with neutrophil-predominant lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

21 January 2018

Antibiotics in asthma

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1-5 (1999-2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Rapid increase in macrolide resistance among penicillin non-susceptible pneumococci in Finland, 1996-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Community prescribing and resistant Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

21 January 2018

Erythromycin ototoxicity

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Who smokes does have more chance to show inguinal hernia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Restoration of cyclic adenosine monophosphate-stimulated chloride channel activity in human cystic fibrosis tracheobronchial submucosal gland cells by adenovirus-mediated and cationic lipid-mediated gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Effects of azithromycin on glutathione S-transferases in cystic fibrosis airway cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Azithromycin for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Evaluation of the immunomodulatory effects of the macrolide antibiotic, clarithromycin, in female B6C3F1 mice: a 28-day oral gavage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

In vitro effects of erythromycin on RANKL and nuclear factor-kappa B by human TNF-alpha stimulated Jurkat cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Erythromycin exerts in vivo anti-inflammatory activity downregulating cell adhesion molecule expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

EM703, a new derivative of erythromycin, inhibits transforming growth factor-beta signaling in human lung fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Suppression of oxidant-induced glutathione synthesis by erythromycin in human bronchial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Roxithromycin downmodulates Th2 chemokine production by keratinocytes and chemokine receptor expression on Th2 cells: its dual inhibitory effects on the ligands and the receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

The nature of small-airway obstruction in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Pulmonary biomarkers in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

The clinical utility of biomarkers in asthma and COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Immunomodulatory effects of macrolide antibiotics - part 2: advantages and disadvantages of long-term, low-dose macrolide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Macrolides as immunomodulatory medications for the therapy of chronic lung diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Macrolide immunomodulation of chronic respiratory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Macrolide immunomodulatory effects and symptom resolution in acute exacerbation of chronic bronchitis and acute maxillary sinusitis: a focus on clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Role of macrolide therapy in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Clarithromycin prevents smoke-induced emphysema in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Routine use of extended-release clarithromycin tablets for short-course treatment of acute exacerbations of non-severe COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Once-daily azithromycin for 3 days compared with clarithromycin for 10 days for acute exacerbation of chronic bronchitis: a multicenter, double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Short-course therapy of acute bacterial exacerbation of chronic bronchitis: a double-blind, randomized, multicenter comparison of extended-release versus immediate-release clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

An open-label, randomized, multicenter, comparative study of the efficacy and safety of 7 days of treatment with clarithromycin extended-release tablets versus clarithromycin immediate-release tablets for the treatment of patients with acute bacteri

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Mechanisms of rhinovirus-induced asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Azithromycin induces anti-viral responses in bronchial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

The indication and effectiveness of low-dose erythromycin therapy in pediatric patients with bronchial asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Erythromycin modulates eosinophil chemotactic cytokine production by human lung fibroblasts in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Interaction of Chlamydia pneumoniae and human alveolar macrophages: infection and inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Anti-inflammatory drug therapy in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Chlamydophila pneumoniae induces a sustained airway hyperresponsiveness and inflammation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Update on infection and antibiotics in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Antibiotics for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Immunomodulatory effects of macrolide antibiotics in respiratory disease: therapeutic implications for asthma and cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Novel strategies for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Potential role of antibiotics in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Macrolide and occult infection in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

A trial of clarithromycin for the treatment of suboptimally controlled asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Macrolides in the treatment of asthma and cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Roxithromycin promotes lymphocyte apoptosis in Dermatophagoides-sensitive asthma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Low-dose, long-term macrolide therapy in asthma: An overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Effect of topical immunomodulators on acute allergic inflammation and bronchial hyperresponsiveness in sensitised rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Clarithromycin targets neutrophilic airway inflammation in refractory asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Evaluation of blood vessels and edema in the airways of asthma patients: regulation with clarithromycin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

The effect of telithromycin in acute exacerbations of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Standardisation of spirometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

A locally active antiinflammatory macrolide (MLD987) for inhalation therapy of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Microbiology of lung infection in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Lower airway inflammation in infants and young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Management of pulmonary disease in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Anti-inflammatory effects of macrolides in lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Macrolides in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Exploring the mechanisms of macrolides in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Azithromycin increases chloride efflux from cystic fibrosis airway epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Effects of azithromycin on the expression of ATP binding cassette transporters in epithelial cells from the airways of cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Antiinflammatory therapies for cystic fibrosis: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

The use of macrolide antibiotics in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Improved lung function and body mass index associated with long-term use of Macrolide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Azithromycin for improving pulmonary function in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Macrolides in cystic fibrosis: is there a role?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Therapy with macrolides in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Azithromycin fails to reduce increased expression of neutrophil-related cytokines in primary-cultured epithelial cells from cystic fibrosis mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Effect of azithromycin on bronchiectasis and pulmonary function in a heart-lung transplant patient with severe chronic allograft dysfunction: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

The concentrations of clarithromycin and its 14-hydroxy metabolite in sputum of patients with bronchiectasis following single dose oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Long-term macrolide therapy in chronic inflammatory airway diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

The macrolide clarithromycin inhibits experimental post-transplant bronchiolitis obliterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Diffuse panbronchiolitis: role of macrolides in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Lung transplantation: the role of azithromycin in the management of patients with bronchiolitis obliterans syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

The effect of long-term treatment with erythromycin on Th1 and Th2 cytokines in diffuse panbronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Effect of maintenance azithromycin on established bronchiolitis obliterans syndrome in lung transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Clarithromycin inhibits overproduction of muc5ac core protein in murine model of diffuse panbronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Analysis of HLA antigens in patients with diffuse panbronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Infection With Highly Pathogenic H7 Influenza Viruses Results in an Attenuated Proinflammatory Cytokine and Chemokine Response Early After Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: implications for treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Systems-level comparison of host-responses elicited by avian H5N1 and seasonal H1N1 influenza viruses in primary human macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

A new therapeutic strategy for lung tissue injury induced by influenza with CR2 targeting complement inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Macrolides: a treatment alternative for bronchiolitis obliterans organizing pneumonia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Bronchiolitis obliterans organizing pneumonia: clinicopathologic review of a series of 45 Korean patients including rapidly progressive form

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Adverse effects of macrolide antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Vancomycin- and erythromycin-induced hearing loss in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Drug intolerance to high-dose clarithromycin among elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Erythromycin-induced hypoacusis: 11 new cases and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Erythromycin ototoxicity: analysis and conclusions based on 22 case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Ototoxicity with azithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Oral erythromycin and the risk of sudden death from cardiac causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Antimicrobial-associated QT interval prolongation: pointes of interest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Macrolide-lincosamide-streptogramin B (MLS) resistance in cutaneous propionibacteria: definition of phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides: a promising strategy or an oriental mystery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Tetracyclines and chemically modified tetracycline-3 (CMT-3) modulate cytokine secretion by lipopolysaccharide-stimulated whole blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Role of chemically modified tetracycline on TNF-alpha and mitogen-activated protein kinases in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Relationship Between Bacterial Flora in Sputum and Functional Impairment in Patients With Acute Exacerbations of COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Effect of 6 Months of Erythromycin Treatment on Inflammatory Cells in Induced Sputum and Exacerbations in Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Daily versus weekly azithromycin in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-1161-X

Host modulation with tetracyclines and their chemically modified analogues

21 January 2018

1 reference

12 December 2020

Successful treatment of a case with rapidly progressive Bronchiolitis obliterans organizing pneumonia (BOOP) using cyclosporin A and corticosteroid.

1 reference

12 December 2020

Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro

1 reference

12 December 2020

In vivo efficacy of Ingavirin against pandemic A (H1N1/09)v influenza virus

1 reference

12 December 2020

[An experimental study on airway inflammation and remodeling in a rat model of chronic bronchitis and emphysema]

1 reference

12 December 2020

A study of poor responders for long-term, low-dose macrolide administration for chronic sinusitis

1 reference

12 December 2020

The effects of macrolides on inflammatory cells

1 reference

12 December 2020

Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group

1 reference

12 December 2020

Organizing pneumonia--clarithromycin treatment

1 reference

12 December 2020

Effect of long-term and low-dose administration of erythromycin on proliferation of T lymphocytes stimulated with mitogens

1 reference

12 December 2020

[Anti-inflammatory effects of macrolides: applications in lung disease]

1 reference

12 December 2020

[Cytokine storm in avian influenza].

1 reference

12 December 2020

Differentiation of resistance phenotypes among erythromycin-resistant streptococci

1 reference

12 December 2020

Cefaclor AF vs Clarithromycin in acute exacerbation of chronic bronchitis (B3M-PK-AJBG)

1 reference

12 December 2020

Comparative effectiveness of macrolides and quinolones for patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD)

1 reference

12 December 2020

G(1) Phase growth arrest and induction of p21(Waf1/Cip1/Sdi1) in IB3-1 cells treated with 4-sodium phenylbutyrate.

1 reference

12 December 2020

Acute exacerbation of COPD: factors associated with poor treatment outcome

1 reference

12 December 2020

[Immunosuppressive macrolides and their use in dermatology]

1 reference

12 December 2020

Macrolides for the treatment of chronic sinusitis, asthma, and COPD.

1 reference

12 December 2020

Macrolide-resistant Mycoplasma pneumoniae in paediatric pneumonia

1 reference

12 December 2020

Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma

1 reference

12 December 2020

[The role of macrolides in treatment of exacerbations of chronic obstructive pulmonary disease]

1 reference

12 December 2020

Organizing pneumonia--own experiences with clarithromycin treatment

1 reference

12 December 2020

Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis

1 reference

12 December 2020

Comparison between azithromycin and amoxicillin in the treatment of infectious exacerbation of chronic obstructive pulmonary disease

1 reference

12 December 2020

The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis

1 reference

12 December 2020

[The imbalance of Th1/Th2 cytokine expression in peripheral blood mononuclear cell from asthmatic patients and the effect of erythromycin on these cytokines]

1 reference

12 December 2020

Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis

1 reference

12 December 2020

Decrease in theophylline clearance after the administration of erythromycin to a patient with obstructive lung disease

1 reference

12 December 2020

[Macrolides, lincosamides, streptogramines (MLS): mechanisms of action and resistance]

1 reference

12 December 2020

MMP inhibition by chemically modified tetracycline-3 (CMT-3) in equine pulmonary epithelial lining fluid

1 reference

12 December 2020

[Bacterial etiology of chronic bronchitis exacerbations treated by primary care physicians]

1 reference

12 December 2020

Long-term clarithromycin in cystic fibrosis: effects on inflammatory markers in BAL and clinical status.

1 reference

12 December 2020

Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome

1 reference

12 December 2020

Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients

1 reference

12 December 2020

Roxithromycin inhibits tumor necrosis factor-alpha-induced matrix metalloproteinase-1 expression through regulating mitogen-activated protein kinase phosphorylation and Ets-1 expression

1 reference

12 December 2020

Approaches to the synthesis of immunolides: selective immunomodulatory macrolides for cystic fibrosis.

1 reference

12 December 2020

Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis

1 reference

12 December 2020

New strains of bacteria and exacerbations of chronic obstructive pulmonary disease

1 reference

12 December 2020

Macrolide antibiotics for cystic fibrosis

1 reference

12 December 2020

MLS resistance phenotypes and mechanisms in beta-haemolytic group B, C and G Streptococcus isolates in La Rioja, Spain

1 reference

12 December 2020

Adjunctive Effects of Cyclosporine and Macrolide in Rapidly Progressive Cryptogenic Organizing Pneumonia with no Prompt Response to Steroid

1 reference

12 December 2020

Phenotypes of staphylococcal resistance to macrolides, lincosamides and streptogramin B (MLS) in a Turkish university hospital

1 reference

12 December 2020

Cryptogenic organizing pneumonitis. The North American experience

1 reference

12 December 2020

Low-dose/long-term erythromycin for treatment of bronchiolitis obliterans organizing pneumonia (BOOP)

1 reference

12 December 2020

Drug-induced torsades de pointes in patients aged 80 years or more

1 reference

12 December 2020

Anti-inflammatory effects of macrolide antibiotics

1 reference

12 December 2020

A pilot study of low-dose erythromycin in bronchiectasis

1 reference

12 December 2020

[Usefulness of macrolides as anti-inflammatories in respiratory diseases]

1 reference

12 December 2020

[Antibiotics for acute exacerbations of chronic obstructive pulmonary disease (COPD)]

1 reference

12 December 2020

Macrolides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains

1 reference

12 December 2020

In vivo immunomodulatory profile of telithromycin in a murine pneumococcal infection model.

1 reference

12 December 2020

The effect of erythromycin on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum

1 reference

12 December 2020

Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma

1 reference

12 December 2020

Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin

1 reference

12 December 2020

Efficacy of long-term macrolide antibiotic therapy in patients with diffuse panbronchiolitis: comparison between HLA-B54-positive and -negative cases

1 reference

12 December 2020

The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis

1 reference

12 December 2020

Human influenza A viruses are proteolytically activated and do not induce apoptosis in CACO-2 cells

1 reference

12 December 2020

Role for 5-day, once-daily extended-release clarithromycin in acute bacterial exacerbation of chronic bronchitis

1 reference

12 December 2020

Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection

1 reference

12 December 2020

The role of azithromycin in patients with cystic fibrosis.

1 reference

12 December 2020

CF-Emerging therapies: Modulation inflammation

1 reference

12 December 2020

Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis

1 reference

12 December 2020

[The macrolide antibiotics in treatment of skin diseases]

1 reference

12 December 2020

Antibiotic prophylaxis for chronic obstructive pulmonary disease: resurrecting an old idea

1 reference

12 December 2020

The pharmacokinetics of azithromycin in human serum and tissues

1 reference

12 December 2020

Novel 12-membered non-antibiotic macrolides from erythromycin A; EM900 series as novel leads for anti-inflammatory and/or immunomodulatory agents

1 reference

12 December 2020

Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study

1 reference

12 December 2020

Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice

1 reference

12 December 2020

Roxithromycin attenuates acid-induced cough and water-induced bronchoconstriction in children with asthma

1 reference

12 December 2020

Immunomodulatory properties of antibiotics

1 reference

12 December 2020

Immuno-modulation and anti-inflammatory benefits of antibiotics: the example of tilmicosin.

1 reference

12 December 2020

Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma

1 reference

12 December 2020

[Demonstration of a mechanism of anti-inflammatory effect of erythromycin on allergic airway inflammation in rat]

1 reference

12 December 2020

Cyclophosphamide in severe steroid-resistant bronchiolitis obliterans organizing pneumonia

1 reference

12 December 2020

Anti-inflammatory approaches to the treatment of cystic fibrosis lung disease: past, present and future

1 reference

12 December 2020

[A clinical trial of 14 and 15 membered macrolides in treating six cases of diffuse panbronchiolitis]

1 reference

12 December 2020

Suppression of cytokine production of human memory T cells by roxithromycin.

1 reference

12 December 2020

Hot topics respiratory infections

1 reference

12 December 2020

Levofloxacin and macrolides in chronic bronchitis exacerbation: comparative analysis of the treatment efficacy and nonrelapsing periods

1 reference

12 December 2020

Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report

1 reference

12 December 2020

Impact of Rokitamycin, a New 16-Membered Macrolide, on Serum Theophylline

1 reference

12 December 2020

Prophylactic antibiotic treatment of bronchiectasis with azithromycin

1 reference

12 December 2020

Early Pulmonary Inflammation in Infants with Cystic Fibrosis

1 reference

12 December 2020

Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma

1 reference

12 December 2020

3. Epithelial injury. Mechanisms and cell biology of airway epithelial injury

1 reference

12 December 2020

Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation

1 reference

12 December 2020

Tissue-directed pharmacokinetics

1 reference

12 December 2020

Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro

1 reference

12 December 2020

Macrolides in cystic fibrosis

1 reference

12 December 2020

Macrolides for chronic asthma

1 reference

12 December 2020

Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin

1 reference

12 December 2020

[Immunization and immuno-modulation for prevention of respiratory tract infections]

1 reference

12 December 2020

Clarithromycin-induced hepatotoxicity

1 reference

12 December 2020

[A randomized comparative study of 3 days of azithromycin treatment and 10 days of cefuroxime treatment in exacerbations in patients with chronic obstructive pulmonary disease]

1 reference

12 December 2020

Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature

1 reference

12 December 2020

Effects of roxithromycin on tumor necrosis factor-alpha-induced vascular endothelial growth factor expression in human periodontal ligament cells in culture

1 reference

12 December 2020

New pharmacological options in the therapy of COPD

1 reference

12 December 2020

[Prospective, comparative study (1994-1998) of the influence of short-term prophylactic treatment with azithromycin on patients with advanced COPD]

1 reference

12 December 2020

GSTM1 and GSTT1 genes analysis in head and neck cancer patients

1 reference

12 December 2020

Macrolide antibiotics, bacterial populations and inflammatory airway disease

1 reference

12 December 2020

Exacerbations of chronic obstructive pulmonary disease: when are bacteria important?

1 reference

12 December 2020

Evaluation of an anti-chlamydial antibiotic therapy influence on asthma patients

1 reference

12 December 2020

A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group

1 reference

12 December 2020

Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease

1 reference

12 December 2020

Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial

1 reference

12 December 2020

Changes in bronchial inflammation during acute exacerbations of chronic bronchitis

1 reference

12 December 2020

Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis

1 reference

12 December 2020

Anti-inflammatory effects of the macrolides.

1 reference

12 December 2020

Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors

1 reference

12 December 2020

Macrolides: new therapeutic perspectives in lung diseases.

1 reference

12 December 2020

Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations

1 reference

12 December 2020

10.1007/S00228-011-1161-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22105373%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference